Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics will present post-hoc data from its Phase Ib/II FELIX study at the ASCO Annual Meeting, focusing on obe-cel in patients with relapsed/refractory B-ALL and extramedullary disease (EMD). The analysis showed a 59% overall response rate and a median duration of response of 42.6 months in the EMD subset, a population typically associated with poorer outcomes.
Key figures
- Drug Name
- obe-cel (obecabtagene autoleucel)
- Phase Of Trial
- Phase Ib/II
- Percent with emd
- 21%
- Patients with emd
- 27
- Total patients infused
- 127
- Overall response rate emd
- 59%
- Median duration of response emd
- 42.6 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.